Compositions and methods for enhancing NK cell activity

Details for Australian Patent Application No. 2005238298 (hide)

Owner Innate Pharma

Inventors Romagne, Francois

Agent Pizzeys

Pub. Number AU-A-2005238298

PCT Pub. Number WO2005/105848

Priority 60/567,058 30.04.04 US

Filing date 29 April 2005

Wipo publication date 10 November 2005

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

16 November 2006 PCT application entered the National Phase

  PCT publication WO2005/105848 Priority application(s): WO2005/105848

25 November 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005238300-Compositions and methods for treating proliferative disorders such as NK-type LDGL

2005238296-Substituted morpholine compounds for the treatment of central nervous system disorders